Low-density Lipoprotein Cholesterol Reduction With State-of-the-art Therapy in Secondary Prevention and Major Cardiovascular Adverse Events: Republic of Srpska Registry (RS-ACS)

University Clinical Centre of Republic of Srpska

Status: Unknown

Conditions: Dyslipidemias; Acute Coronary Syndrome

Treatments: Drug: Statin

Study type: Observational

Funder types: Other

Identifiers

NCT05081336

022021

Details and patient eligibility

About

Recent trials have demonstrated that a reduction in low-density lipoprotein cholesterol (LDL-C) reduces cardiovascular adverse events following acute coronary syndrome (ACS). However, the data coming from the real-world setting are limited. Therefore, the aim of the study is to assess the association between LDL-C changes with prognosis in patients who survive ACS.

Patients with ACS will be followed for mortality and major events for at least 1 year. Changes in LDL-C between the ACS and a 6- to 10-week follow-up visit will be analysed. The associations between quartiles of LDL-C change and therapy intensity with outcomes will be investigated using adjusted Cox regression analyses.

Enrollment: 500 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• acute coronary syndrome

Exclusion criteria

Trial design

500 participants in 3 patient groups

High-intensity statin

Treatment:

Drug: Statin

High-intensity statin plus ezetimib

Treatment:

Drug: Statin

High-intensity statin plus ezetimib plus PCSK9 inhibitor

Treatment:

Drug: Statin